A Study of AL102 in Patients With Progressing Desmoid Tumors
Trial details
- Registry ID
- NCT04871282
- Phase
- Phase 2, Phase 3
The PDUFA goal date for AL102 (varegacestat) is 28 Apr 2027, as disclosed by Immunome, Inc. (IMNM).
Drug identity checked against registry records
Also recorded as varegacestat
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of AL102 in Patients With Progressing Desmoid TumorsNCT04871282 | IMNM | Phase 2, Phase 3 | Active not recruiting | 2025-12-03Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2027-04-28Day | AL102Immunome, Inc. · IMNM | Company-disclosed PDUFA goal dateAnnounced review target | Not specified | Open original sourceRead source excerptan NDA for varegacestat to the FDA, which was assigned a PDUFA target action date of April 28, 2027 First seen: 11 Nov 2026 · Evidence last checked: 11 Nov 2026 |
| 2027-04-28Day | AL102Immunome, Inc. · IMNM | Company-disclosed PDUFA goal dateAnnounced review target | Not specified | Open original sourceRead source excerptVaregacestat PDUFA target action date of April 28, 2027 First seen: 11 Nov 2026 · Evidence last checked: 11 Nov 2026 |